Antares Pharma, Inc. (ATRS)

Discussion in 'Men's Economics' started by Michael Scally MD, May 22, 2018.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Antares Pharma, Inc. (ATRS)
    ATRS : Summary for Antares Pharma, Inc. - Yahoo Finance


    Antares Pharma: Excellent Risk-Reward Profile
    Antares Pharma: Excellent Risk-Reward Profile - Antares Pharma Inc. (NASDAQ:ATRS) | Seeking Alpha

    Summary
    · The current share price remains well below reasonable valuation of expectations.
    · Article will discuss financial and milestone expectations for the remainder of 2018.
    · Company remains a viable acquisition candidate, especially in the likely aftermath of Xyosted being approved by the FDA.
    · Regardless of the direction the company takes, its profitable business model is set for fulfillment.

    In the aftermath of Antares Pharma (ATRS) falling from $4.09 in mid-October to $1.58 by mid-November 2017 after it was learned that the FDA had issued a CRL for the company's TRT (testosterone replacement therapy) drug Xyosted, the stock has made a slow comeback beginning in December to a current price near $2.50. Since mid-December the shares have resumed an upward trend, steadily making higher highs, retreating to higher lows. With 200-day average trading volume near 1.5 million shares per day, volume in the last 30 days has dropped to less than half at 729,000, suggesting that the market has capitulated to under-performance. However, building fundamentals support a position that the remainder of 2018 will unfold much differently than 2017. While Antares stock has remained a highly volatile investment during the time frame covered by the author, it is highly doubtful it will ever see $2.00 again. By year-end, the share price should exceed $5.00 and has the potential to trade much higher in the next 12 months.
     
  2. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    ANTARES RECEIVES FDA APPROVAL OF XYOSTED™ (testosterone ENANTHATE) INJECTION FOR TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES
    https://www.antarespharma.com/application/files/2715/3835/7488/XYOSTED_FDA_Approval_Final.pdf

    A Novel Subcutaneous Auto Injector Product Approved For Once-Weekly At-Home Therapy

    Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval of XYOSTED™ (testosterone enanthate) injection by the U.S. Food and Drug Administration (FDA). XYOSTED™ is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. XYOSTED™ has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (see Indications and Usage below).

    BOXED WARNING: BLOOD PRESSURE INCREASES

    · XYOSTED™ can cause blood pressure increases that can increase the risk for major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, with greater risk for MACE in patients with cardiovascular risk factors or established cardiovascular disease.

    · Before initiating XYOSTED™, consider the patient’s baseline cardiovascular risk and ensure blood pressure is adequately controlled.

    · Starting approximately 6 weeks after initiating therapy, periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension in patients on XYOSTED™.

    · Re-evaluate whether the benefits of XYOSTED™ outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease while on treatment.

    · Due to this risk, use XYOSTED™ only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.
     
  3. Dw725

    Dw725 Member

    Interesting product for the trt crowd. Although 100 mg weekly seems on the low side for being their highest dosage available, maybe I am mistaken.
     
  4. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Antares Announces Commercial Availability Of XYOSTED Injection
    https://www.antarespharma.com/application/files/3315/4350/0065/XYOSTED_now_available_final.pdf

    Antares Pharma Inc. ( ATRS ) announced the availability of XYOSTED or testosterone enanthate injection.

    XYOSTED is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector.

    XYOSTED has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

    XYOSTED was approved by the U.S. Food and Drug Administration on September 28, 2018.